PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

Sponsor
Peking University Third Hospital
Study ID
NCT06792162
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Carilizumab and Apatinib — DRUG
    After every 2 cycles of meparticipants. Apatinib was discontinued for one cycle and an additional course of Carilizumab was administered in preparation for surgery. The time between the last dose and surgery was 3-6 weeks, with a maximum of 6 weeks. Both surgical and non-surgical participants will continue to receive treatment with the original regimen of Carilizumab combined with Apatinib after surgery until disease progression, recurrence, or death, for a maximum of 2 years.

Study Details

Evaluate the safety and efficacy of PD-1 antibody Carilizumab combined with apatinib for the conversion therapy of unresectable stage III and IV dMMR gastric cancer.

Key Dates

Start date
Apr 20, 2023
Status verified
Nov 2024
Primary completion
Apr 30, 2026
Completion
Apr 30, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: PD-1 antibody Carilizumab combined with apatinib for unresectable dMMR gastric cancer
    Participants will receive Carilizumab 200mg repeated every 21 days and Apatinib 250mg everyday

Primary Outcome Measure

The rate of 1-year PFS [ Time Frame: From enrollment to the end of treatment at 1year" ]

Central Contacts

Related Studies